The Tech Park Basel is the premier address for early-stage tech start-ups in Basel. It offers a collaboration-friendly, yet business-driven environment and is part of the rapidly growing Stücki Park in the dynamic northern part of Basel. The Tech Park Basel provides office space and fully equipped laboratories at highly favorable terms, and offers shared facilities and a variety of other services to tech start-ups.
The Tech Park Basel offers modern office space, and fully equipped, state-of-the-art laboratories at favorable conditions.
More Information
The Tech Park Basel provides various comprehensive services for your convenience and on your journey of business success.
More Information
Benefit from various meeting rooms and services for your convenience including the organisation of events and promoting transfer of knowledge.
More Information
Join a modern and diverse collaboration- and business-friendly environment in a vibrant and inclusive community of a thriving environment.
More Information
by Tech Park Basel
31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...
by Administrator
05.01.2023
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment...
by Tech Park Basel
26.10.2022
We are pleased to announce that Christian Harr (current COO) will become the new CEO of Tech Park Basel. He will take up the new position on...
by Tech Park Basel
23.09.2022
Impressive first edition: The Regio Basel 2022 Industry Night was also a great success at Tech Park Basel. 44 companies from Basel and the region opened their ...
by Tech Park Basel
22.08.2022
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville...
by Tech Park Basel
10.08.2022
Versant has made a $30 million Series A commitment to Vector, which is the most recent company to be launched out of the ...
by Administrator
22.06.2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient...
by Tech Park Basel
21.06.2022
BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098...
by Tech Park Basel
08.06.2022
BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR...
by Tech Park Basel
29.04.2022
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to ...
by Tech Park Basel
18.03.2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire...
by Tech Park Basel
21.12.2021
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led...
by Tech Park Basel
16.12.2021
Cellestia Biotech AG (Cellestia) is a fully integrated R&D company specialised in the discovery and development of first-in-class...
by Tech Park Basel
14.12.2021
Kinarus AG has been awarded a grant from the Swiss Federal Funding Programme for the development of COVID-19 Medicines...
by Tech Park Basel
04.11.2021
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference...
by Tech Park Basel
14.09.2021
Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with...
by Tech Park Basel
27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
by Tech Park Basel
29.06.2021
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...
by Tech Park Basel
15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.
by Tech Park Basel
14.06.2021
The Technologiepark Basel and the Swiss Biotech Association invite you to a virtual talk about: ‘How to attract and retain best talents for Life Sciences startups’.
by Administrator
by Tech Park Basel
31.05.2021
Kinarus is working on a drug against Covid-19, which is also intended to combat typical Long Covid symptoms. The medicament is aimed to be launched on the market in 2022.
by Tech Park Basel
11.05.2021
Der Tech Park Basel wurde über die letzten zehn Jahre im Stücki Park im Norden von Basel auf- und ausgebaut. Heute bietet er auf rund 6'700 m2 für über 30 innovative, technologieorientierte Start-ups ein inspirierendes Umfeld und verleiht der Wirtschaft im Kanton Basel- Stadt wichtige Impulse.
by Tech Park Basel
05.05.2021
Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.
John Castle Chief Data Science Officer of Monte Rosa Therapeutics
to the full story
Michael Bauer CEO Cellestia Biotech
to the full story
Ulf Grawunder, Founder of NBE Therapeutics
to the full storyBarry Hardy CEO of Edelweiss Connect
to the full story
